Meeting
ASCO Plenary Series
Relatlimab and nivolumab versus nivolumab in previously untreated metastatic or unresectable melanoma: Overall survival and response rates from RELATIVITY-047 (CA224-047)
Presenter
Georgina V. Long, MD, PhD, FRACP
Melanoma Institute Australia, The University of Sydney, Royal North Shore and Mater Hospitals
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Videos & Slides Details
Session Type
Plenary Session
Session Title
ASCO Plenary Series: March 2022 Session
Track
Special Sessions,Lung Cancer,Melanoma/Skin Cancers
Sub Track
Melanoma/Skin Cancers
Clinical Trial Registration Number
NCT03470922
Citation
J Clin Oncol 40, 2022 (suppl 36; abstr 360385)
DOI
10.1200/JCO.2022.40.36_suppl.360385
Abstract #
360385
Abstract Disclosures
Similar Videos & Slides
Videos & Slides
ASCO Plenary Series
Discussion of Abstract 360385: Relatlimab and nivolumab versus nivolumab in previously untreated metastatic or unresectable melanoma: Overall survival and response rates from RELATIVITY-047 (CA224-047).
Speaker: Adil Daud, MD
Videos & Slides
2022 ASCO Annual Meeting
Updates on Abstract 360385: Relatlimab and nivolumab versus nivolumab in previously untreated metastatic or unresectable melanoma: Overall survival and response rates from RELATIVITY-047 (CA224-047)
Speaker: Georgina V. Long, MD, PhD, FRACP
Videos & Slides
2023 ASCO Annual Meeting
Nivolumab (NIVO) plus relatlimab (RELA) vs NIVO in previously untreated metastatic or unresectable melanoma: 2-year results from RELATIVITY-047.
Speaker: Hussein A. Tawbi, MD, PhD
Videos & Slides
2022 ASCO Annual Meeting
Nivolumab (NIVO) + relatlimab (RELA) versus NIVO in previously untreated metastatic or unresectable melanoma: OS and ORR by key subgroups from RELATIVITY-047.
Speaker: Hussein A. Tawbi, MD, PhD,